A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT®) Randomized Controlled Trial
Authors:
- Simeon StoinovSSSimeon Stoinov
- Vladimir SimanenkovVSVladimir Simanenkov
- Larisa V. DudarLDLarisa V. Dudar
- Waldemar KarnafelWKWaldemar Karnafel
- Luis Chaires GarciaLGLuis Chaires Garcia
- Alicia M. SambuelliASAlicia M. Sambuelli
- Geert D'HaensGDGeert D'Haens
- Christoph GascheCGChristoph Gasche
- 1 May 2008
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 103 (5) , 1182-1192
Abstract
Anemia is a common complication of inflammatory bowel diseases (IBD) This multicenter study tested the noninferiority and safety of a new intravenous iron preparation, ferric carboxymaltose (FeCarb), in comparison with oral ferrous sulfate (FeSulf) in reducing iron deficiency anemia (IDA) in IBD. Two hundred patients were randomized in a 2:1 ratio (137 FeCarb:63 FeSulf) to receive FeCarb (maximum 1,000 mg iron per infusion) at 1-wk intervals until the patients' calculated total iron deficit was reached or FeSulf (100 mg b.i.d.) for 12 wk. The primary end point was change in hemoglobin (Hb) from baseline to week 12. The median Hb improved from 8.7 to 12.3 g/dL in the FeCarb group and from 9.1 to 12.1 g/dL in the FeSulf group, demonstrating noninferiority (P= 0.6967). Response (defined as Hb increase of >2.0 g/dL) was higher for FeCarb at week 2 (P= 0.0051) and week 4 (P= 0.0346). Median ferritin increased from 5.0 to 323.5 mug/L at week 2, followed by a continuous decrease in the FeCarb group (43.5 mug/L at week 12). In the FeSulf group, a moderate increase from 6.5 to 28.5 mug/L at week 12 was observed. Treatment-related adverse events (AEs) occurred in 28.5% of the FeCarb and 22.2% of the FeSulf groups, with discontinuation of study medication due to AEs in 1.5% and 7.9%, respectively. FeCarb is effective and safe in IBD-associated anemia. It is noninferior to FeSulf in terms of Hb change over 12 wk, and provides a fast Hb increase and a sufficient refill of iron stores.Keywords
This publication has 26 references indexed in Scilit:
- Systematic review: managing anaemia in Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2006
- Presence of the iron exporter ferroportin at the plasma membrane of macrophages is enhanced by iron loading and down-regulated by hepcidinBlood, 2005
- Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trialAlimentary Pharmacology & Therapeutics, 2005
- Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2005
- Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its InternalizationScience, 2004
- A Study for the Evaluation of Safety and Tolerability of Intravenous High-Dose Iron Sucrose in Patients with Iron Deficiency Anemia due to Gastrointestinal BleedingZeitschrift für Gastroenterologie, 2004
- Iron, anaemia, and inflammatory bowel diseasesGut, 2004
- Intake of dietary iron is low in patients with Crohn's disease: a case–control studyBritish Journal of Nutrition, 2004
- The MOS 36-ltem Short-Form Health Survey (SF-36)Medical Care, 1992
- Iron Absorption and Iron Deficiency in Infants and Children with Gastrointestinal DiseasesJournal of Pediatric Gastroenterology and Nutrition, 1992